PR85555

HYDERABAD, India and SEOUL, South Korea, Sept. 15, 2020 /PRNewswire=KYODO JBN/--

    Excelra [https://www.excelra.com/ ], a global data science and data

analytics company, today announced its collaboration with Standigm Inc., a

company using artificial intelligence (AI) technology for drug discovery and

development.

    Under the agreement, Excelra will provide its small molecule medicinal chemistry

intelligence platform GOSTAR [https://www.excelra.com/discovery/#gostar ]

to Standigm Inc. GOSTAR provides comprehensive information encompassing

over 8 million compounds, manually curated from 3 million patents and 200,000

journal articles. The database contains over 28 million SAR associated data points.

The well-structured relational database can be utilised for diverse applications

across different stages of the drug discovery and development lifecycle and aids

in target validation, hit Identification, early lead Identification and optimization.  

Hanjo Kim, Platform Team Leader, Standigm Inc., said: "For an AI-based drug

discovery company, high quality SAR data is of great importance. Our platform

technologies, Standigm BEST(TM), Standigm ASK(TM), and Standigm Insight(TM)

integrate lots of data to generate innovative ideas including finding novel

targets, developing predictive models, and designing novel lead series

compounds. I expect GOSTAR can help this process."

    Raveendra Dayam, Director Chemistry Services, Excelra said: "GOSTAR is the

largest source for experimentally determined interactions of millions of small

molecules with most of the potential drug targets. The platform provides a

comprehensive overview of millions of compounds, linking chemical structure to

biological, pharmacological and therapeutic activities.  These datasets are

core to the AI/ML driven drug discovery programs that support rapid discovery

of novel drug candidates.

About Standigm:

    Standigm Inc. is an Artificial Intelligence (AI)-driven drug discovery

company. Applying its own innovative AI to the real world, Standigm Inc.

eliminates uncertainty in the drug discovery process and develops therapeutic

candidates that are primed for success. Pursuing a full-stack, AI-driven

industrializing drug discovery, Standigm Inc. has achieved the automation of

molecular design workflow (Dark MolFactory(TM)) and the automation effort has

been expanding to the whole drug discovery process based on Standigm AI

platforms, including Standigm ASK(TM) (Target discovery), Standigm BEST(TM)

(Lead selection), and Standigm Insight(TM) (Drug repurposing).

Visit: www.standigm.com

    Contact:  business@standigm.com

    About Excelra:

    Excelra's data science and data analytics solutions empower innovation in

life sciences. The Excelra Edge comes from a seamless amalgamation of

proprietary data assets, domain expertise and data science, to accelerate drug

discovery and development. www.excelra.com

    Media Contact:

    Dorothy Paul

    Director Marketing

    Email:  dorothy.paul@excelra.com

    Logo: https://mma.prnewswire.com/media/692189/Excelra_Logo.jpg 

    SOURCE: Excelra Knowledge Solutions Pvt Ltd